Krebs Biochemicals & Industries (BSE: 524518) is a Visakhapatnam, Andhra Pradesh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹128 Cr, it ranks #3,056 by market cap among the 6,137 Indian listed companies on FinBizNet, and #68 of 86 in Medicinal Chemicals and Botanical Products. At ₹51.85 (as of 25 Oct 2026), the share price is 32.5% below its 52-week high of ₹76.85 and 35.3% above its 52-week low of ₹38.33. The share price is down 27.0% over one year and down 0.1% over three months.
| Current Price | ₹51.85 |
|---|---|
| Market Cap | ₹128 Cr |
| BSE Code | 524518 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -7.5 |
| Return on Equity | 10.96% |
| Return on Assets | -3.75% |
| 52-Week Range | ₹38.33 – ₹76.85 |
| 1-Year Price Change | -27.0% |
| 3-Month Price Change | -0.1% |
| Beta (1Y) | 0.83 |
| Dividend Yield | 0.00% |
| Headquarters | Visakhapatnam, Andhra Pradesh |
| Website | krebsbiochem.com |
| Revenue | ₹7 Cr |
|---|---|
| Net Profit | ₹-2 Cr |
| Net Margin | -35.5% |
| EPS (Basic) | ₹-1.15 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
1. Segment Adjustment-This segment manufactures active pharmaceutical ingredients. 2. Pharma-This segment produces potato crisps. It also engages in the manufacture and sale of sugar. 3. Food-This segment manufactures sugar. 4. Sugar-0
1. Pharma-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Krebs Biochemicals & Industries | ₹128 Cr | -7.5 | 10.96% | ₹7 Cr | -27.0% |
Listed by market capitalisation. Ratios are shown for context only.
Krebs Biochemicals & Industries is trading at ₹51.85, with a market capitalisation of ₹128 Cr.
Krebs Biochemicals & Industries operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Krebs Biochemicals & Industries has a P/E of -7.5 and a return on equity of 10.96%.
Krebs Biochemicals & Industries is listed on the BSE under the scrip code 524518.
Krebs Biochemicals & Industries's share price is down 27.0% over one year and down 0.1% over three months. Its 52-week range is ₹38.33 to ₹76.85.
In Q1 FY27, Krebs Biochemicals & Industries reported revenue of ₹7 Cr and net profit of ₹-2 Cr, with basic EPS of ₹-1.15 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.